How Michigan’s downtowns survived the pandemic
Updated 12:25 PM;
Facebook Share
Within days of the first COVID-19 case being reported in Michigan, Sue Huggett walked door-to-door asking downtown Kalamazoo businesses to participate in the Gift Card Stimulus program.
As the events director for the Kalamazoo Downtown Partnership, Huggett’s duties became solely focused on business support. Doors were closing and the weight of the novel coronavirus was setting in.
In five days, Huggett collected 2,000 gift cards from 66 businesses. She set up a mailing station in her home and sent the gift cards directly to purchasers. The downtown partnership added $10 to every $25 gift card purchased. The initiative brought $70,000 to downtown businesses within a week.
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses
Bristol Myers Squibb (BMS) and Exelixis have revealed new analyses from a phase 3 study of their Opdivo and Cabometyx combination in kidney cancer.
The updated results come from the phase 3 CheckMate-9ER trial, which compared BMS’ checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ tyrosine kinase inhibitor (TKI) Cabometyx to Pfizer’s older drug Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma (RCC) – the most common type of kidney cancer in adults.
After a median follow-up of two years, the Opdivo/Cabometyx combination continued to demonstrate superior progression-free survival (PFS), objective response rate (ORR) and overall survival (OS) compared to Sutent.